# Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>abdominal hysterectomy risk of persistent post-operative pain</td>
<td>46</td>
</tr>
<tr>
<td>A-beta fibers</td>
<td>8, 14–15</td>
</tr>
<tr>
<td>acetaminophen 211–212 sites of analgesic activity</td>
<td>59</td>
</tr>
<tr>
<td>See also tramadol plus acetaminophen. acetaminophen injectable</td>
<td></td>
</tr>
<tr>
<td>acetaminophen oral and rectal 256–7 acid sensing ion channels (ASICs)</td>
<td></td>
</tr>
<tr>
<td>ACTIQ™, 131</td>
<td></td>
</tr>
<tr>
<td>Acurox™ formulation, 466</td>
<td></td>
</tr>
<tr>
<td>acute pain, 5–6, 13 addiction</td>
<td></td>
</tr>
<tr>
<td>See opioid dependence, 170</td>
<td></td>
</tr>
<tr>
<td>A-delta fibers, 3, 8–9, 14</td>
<td></td>
</tr>
<tr>
<td>adenosine receptor agonists/antagonants, Adlea™, 500</td>
<td></td>
</tr>
<tr>
<td>Adolonta, 137</td>
<td></td>
</tr>
<tr>
<td>adrenergic and serotoninergic pain suppression</td>
<td></td>
</tr>
<tr>
<td>adrenergic and serotoninergic receptors, 328</td>
<td></td>
</tr>
<tr>
<td>descending pain pathways, 329</td>
<td></td>
</tr>
<tr>
<td>norepinephrine, 329</td>
<td></td>
</tr>
<tr>
<td>serotonin, 329</td>
<td></td>
</tr>
<tr>
<td>Advil™, 215</td>
<td></td>
</tr>
<tr>
<td>AeroLEFT™, 444</td>
<td></td>
</tr>
<tr>
<td>Ahist™, 391</td>
<td></td>
</tr>
<tr>
<td>Akatinol, 319</td>
<td></td>
</tr>
<tr>
<td>Akten, 279</td>
<td></td>
</tr>
<tr>
<td>Alavert™, 391</td>
<td></td>
</tr>
<tr>
<td>Algix, 243</td>
<td></td>
</tr>
<tr>
<td>Allegra®, 391</td>
<td></td>
</tr>
<tr>
<td>Aller-chlor®, 391</td>
<td></td>
</tr>
<tr>
<td>Alleve™, 221</td>
<td></td>
</tr>
<tr>
<td>allodynia, 5, 14, 16, 24, 30, 76</td>
<td></td>
</tr>
<tr>
<td>alpha-2 adrenergic agonists sites of analgesic activity, 62</td>
<td></td>
</tr>
<tr>
<td>alvimopan, 420–22</td>
<td></td>
</tr>
<tr>
<td>bowel obstruction patients, 422</td>
<td></td>
</tr>
<tr>
<td>amantadine, 313, 326–7</td>
<td></td>
</tr>
<tr>
<td>American Society of Anesthesiologists Task Force on Acute Pain Management, 211</td>
<td></td>
</tr>
<tr>
<td>amethocaine gel. See Ametop Gel™</td>
<td>283–7</td>
</tr>
<tr>
<td>Ametop Gel™, 283–7</td>
<td></td>
</tr>
<tr>
<td>amputation risk of persistent post-operative pain, 46</td>
<td></td>
</tr>
<tr>
<td>Amrix, 362</td>
<td></td>
</tr>
<tr>
<td>Anacin™, 252</td>
<td></td>
</tr>
<tr>
<td>analgesic gaps, 53</td>
<td></td>
</tr>
<tr>
<td>analgesic ladder (WHO), 253</td>
<td></td>
</tr>
<tr>
<td>analgesic sites of action, 62</td>
<td></td>
</tr>
<tr>
<td>analgesic targets. See novel targets for new analgesics analgesics and adjunct agents interference with pain signaling, 1 variety available, 1 Anaprox™, 221</td>
<td></td>
</tr>
<tr>
<td>Anesject™, 316</td>
<td></td>
</tr>
<tr>
<td>Anestacon, 279</td>
<td></td>
</tr>
<tr>
<td>Anforin™, 157</td>
<td></td>
</tr>
<tr>
<td>antibody PG110, 513</td>
<td></td>
</tr>
<tr>
<td>anticoagulants and regional anesthesia, 210</td>
<td></td>
</tr>
<tr>
<td>anticoagulated patients, 205</td>
<td></td>
</tr>
<tr>
<td>antiplatelet agents, 207</td>
<td></td>
</tr>
<tr>
<td>complications in peripheral nerve blocks, 209</td>
<td></td>
</tr>
<tr>
<td>direct thrombin inhibitors (DTIs), 208</td>
<td></td>
</tr>
<tr>
<td>fondaparinux (Arixtra), 207</td>
<td></td>
</tr>
<tr>
<td>heparin, 206</td>
<td></td>
</tr>
<tr>
<td>herbal therapies, 208</td>
<td></td>
</tr>
<tr>
<td>low molecular weight heparin (LMWH), 207</td>
<td></td>
</tr>
<tr>
<td>oral anticoagulants (warfarin), 207</td>
<td></td>
</tr>
<tr>
<td>potential complications, 206</td>
<td></td>
</tr>
<tr>
<td>anticonvulsant analgesics, 294</td>
<td></td>
</tr>
<tr>
<td>adverse effects, 293</td>
<td></td>
</tr>
<tr>
<td>first generation drugs, 292</td>
<td></td>
</tr>
<tr>
<td>mechanisms of action, 292</td>
<td></td>
</tr>
<tr>
<td>second generation drugs, 292</td>
<td></td>
</tr>
<tr>
<td>anticonvulsants 341–5</td>
<td></td>
</tr>
<tr>
<td>sites of analgesic activity, 60</td>
<td></td>
</tr>
<tr>
<td>link between pain and depression, 338</td>
<td></td>
</tr>
<tr>
<td>monoamine oxidase inhibitors (MAOIs), 338</td>
<td></td>
</tr>
<tr>
<td>SNRIs, 341</td>
<td></td>
</tr>
<tr>
<td>SSRIs, 338</td>
<td></td>
</tr>
<tr>
<td>tricyclic antidepressants (TCAs), 338</td>
<td></td>
</tr>
<tr>
<td>antidepressants sites of analgesic activity, 62</td>
<td></td>
</tr>
</tbody>
</table>
routes of administration, 240
trade name, 238
Centers for Epidemiologic Studies Depression scale (CES-D), 345
central pain, 6
central pain syndrome, 23
central sensitization, 24
Cesamet®, 492
Cesarean section risk of persistent post-operative pain, 46
chloride (Cl-) channels, 255
Chlor-Trimeton®, 391
chlorzoxazone, 360
chronic pain, 6, 14
chronic post-surgical pain See persistent post-operative pain
CHRONOGESICTM, 467
Clarinex®, 391
Claritin®, 391
classification of pain approaches to classification, 3
neuropathic pain, 4
nociceptive pain, 3–4
physiological pain, 3–4
clinical effects of pain, 3
clinical implications of hyperalgesia, 22
clonidine (neuraxial)
See neurexial clonidine hydrochloride, 332
clonidine (transdermal and parenteral), 332
chemical name, 330
chemical structure, 330
common doses, 331
contraindications, 331
description, 330
drug clearance and elimination, 331
drug related adverse events, 332
indications (approved/non-approved), 331
major and minor sites of action, 330
manufacturers, 330
metabolic pathways, 331
mode of activity, 331
potential advantages, 331
potential disadvantages, 332
receptor interactions, 331
trade/proprietary names, 330
CNS pain pathophysiology, 24
cocaine discovery of local anesthetic properties, 267
codeine, 100
description, 99
drug class, 98
drug related adverse events, 100
generic name, 98
indications, 99
manufacturer, 98
metabolic pathways, 99
mode of activity, 99
potential advantages, 100
potential disadvantages, 100
sites of activity, 99
trade/proprietary names, 98
cognitive behavior therapy (CBT), 33
cognitive therapy, 33
combination analgesics See Fioricet; Fiorinal
Cymbalta, 353
Cytochrome CYP2D6 genetic variations, 39
cytokine family, 438
cytokines, 8
damason-P®, 112
dantroline, 362
decadron®, 388
delta-9-tetrahydrocannabinol. See cannabinoid agonists
deltacortisone®, 388
deltadehydrocortisone®, 388
deltasone®, 388
demorol®, 94
depakene, 292
depakon, 292
depobupivacaine, 471
DepoDur®, 194
depression and pain. See antidepressant analgesics
descending control of pain, 12
descending pain pathways, 329
desyl®, 351
DETERx technology, 465
dexamethasone chemical name, 388
description, 370
chemical structure, 370
common doses/uses, 371
contraindications, 371
cost, 371
description, 370
drug class, 370
drug clearance and elimination, 370
drug related adverse events, 371
generic name, 370
indications (approved/non-approved), 370
manufacturers, 370
metabolism, 370
overdose, 371
potential advantages, 371
potential disadvantages, 371–372
proprietary name, 370
side effects, 372
cyclooxygenase (COX), 25
cyclooxygenase (COX) enzymes, 212
cyclooxygenase-2 (COX-2), 15
Cymbalta, 353
cytochrome CYP2D6 genetic variations, 39
damason-P®, 112
dantroline, 362
decadron®, 388
delta-9-tetrahydrocannabinol. See cannabinoid agonists
deltacortisone®, 388
deltadehydrocortisone®, 388
deltasone®, 388
demorol®, 94
depakene, 292
depakon, 292
depobupivacaine, 471
depoDur®, 194
depression and pain. See antidepressant analgesics
descending control of pain, 12
descending pain pathways, 329
desyl®, 351
DETERx technology, 465
dexamethasone chemical name, 388
description, 370
chemical structure, 370
common doses/uses, 371
contraindications, 371
cost, 371
description, 370
drug class, 370
drug clearance and elimination, 370
drug related adverse events, 371
generic name, 370
indications (approved/non-approved), 370
manufacturers, 370
metabolism, 370
overdose, 371
potential advantages, 371
potential disadvantages, 371–372
proprietary name, 370
side effects, 372
<table>
<thead>
<tr>
<th>Potential disadvantages, proprietary names, side effects</th>
<th>390</th>
</tr>
</thead>
<tbody>
<tr>
<td>dexametomidine, chemical name, chemical structure, common doses and uses, contraindications, drug class, drug related adverse events, generic name, indications, manufacturers, mode of activity, potential advantages, proprietary name</td>
<td>33, 335, 337, 335, 336, 335, 336, 337, 335, 336, 335, 335, 336, 335</td>
</tr>
<tr>
<td>DexPak®, dextromethorphan, brand names/trade names, chemical formula, chemical name, chemical structure, common doses/uses, contraindications, description, drug class, drug related adverse events, generic name, indications, manufacturer, mode of activity, potential advantages, proprietary name</td>
<td>388, 313, 321, 325, 315, 321, 321, 323, 323, 323, 323, 323, 323, 323, 323, 323, 323, 323, 323, 323, 323, 323, 323</td>
</tr>
</tbody>
</table>
potential disadvantages, 356
precautions, 354
proposed mechanism of action, 354
receptor interactions, 354
symptom management, 204
epidural fentanyl, 186
chemical structure, 184
cost, 193
chronic pain patients, 192
cumulative doses/uses, 192
contraindications, 192
treatment of adverse events, 192
epidural patient-controlled analgesia (PCA), 199
generic name, 187
indications, 188
major and minor sites of action, 187
manufacturer, 187
metabolic pathways, 188
potential advantages, 189
potential disadvantages, 189
mode of activity, 189
epidural hydromorphone, 190
generic name, 187
chemical structure, 187
continuous epidural infusion, 188
contraindications, 188
description, 187
epidural patient-controlled analgesia (PCA), 199
epidural fentanyl, 186
generic name, 187
indications, 188
intermittent bolus dosing, 188
manufacturer, 187
epidural hydromorphone, 190
drugs, 189
epidural fentanyl, 186
drug interactions, 183–184
generic name, 187
epidural patient-controlled analgesia (PCA), 199
epidural fentanyl, 186
discussion, 188
epidural patient-controlled analgesia (PCA), 199
generic name, 187
indications, 188
epidural patient-controlled analgesia (PCA), 199
epidural fentanyl, 186
intermittent bolus dosing, 188
manufacturer, 187
epidural hydromorphone, 190
availability, 183
chemical structure, 181
cost, 193
chronic pain patients, 192
cumulative doses/uses, 192
contraindications, 192
epidural morphine, 184
treatment of adverse events, 184
epidural patient-controlled analgesia (PCA), 199
generic name, 187
indications, 188
major and minor sites of action, 187
manufacturer, 187
metabolic pathways, 188
potential advantages, 189
potential disadvantages, 189
mode of activity, 189
epidural hydromorphone, 190
generic name, 187
chemical structure, 187
continuous epidural infusion, 188
contraindications, 188
description, 187
epidural patient-controlled analgesia (PCA), 199
generic name, 187
indications, 188
intermittent bolus dosing, 188
manufacturer, 187
epidural hydromorphone, 190
availability, 183
cost, 193
chronic pain patients, 192
cumulative doses/uses, 192
contraindications, 192
epidural morphine, 184
epidural patient-controlled analgesia (PCA), 199
generic name, 187
indications, 188
major and minor sites of action, 187
manufacturer, 187
epidural hydromorphone, 190
drugs, 189
epidural fentanyl, 186
drug interactions, 183–184
generic name, 187
epidural patient-controlled analgesia (PCA), 199
generic name, 187
indications, 188
epidural patient-controlled analgesia (PCA), 199
generic name, 187
indications, 188
epidural hydromorphone, 190
availability, 183
cost, 193
chronic pain patients, 192
cumulative doses/uses, 192
contraindications, 192
treatment of adverse events, 192
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
equitherapeutics, 213
chemical name, 243
chemical structure, 243
drug class, 243
drug clearance and elimination, 243
drug related adverse events, 243
### Habitrol, 484

### Helicobacter pylori, 213

### histamine, 8

### hydrocodone, 99

**See also:** opioid plus ibuprofen compounds.

### hydrocodone bitartrate, 112–114
- chemical formula, 112
- chemical name, 112
- chemical structure, 112
- common doses, 114
- contraindications, 113–114
- description, 112
- drug class, 112
- drug related adverse events, 114
- generic names, 112
- indications (approved and non-approved), 113
- major and minor sites of action, 112
- manufacturers, 112
- metabolic pathways, 113
- mode of activity, 113
- potential advantages, 114
- potential disadvantages, 112
- proprietary names, 112
- receptor interactions, 112
- hydromorphone extended release, 448–451
  - adverse effects, 451
  - chemical formula, 448
  - chemical name, 448
  - chemical structure, 448
  - contraindications, 451
  - description, 448–449
  - drug class, 448
  - formulations, 449–451
  - generic name, 448
  - indications, 450–451
  - manufacturers, 448
  - mode of action, 447
  - proprietary/trade names, 448
  - hydromorphone OROS™ technology, 467, 469
  - IL-1 (interleukin-1), 15, 39
  - IL-1β, 435
- IL-6, 435
- indomethacin, 229
- inflammatory pain, 15
- inflammatory response, 24–25
- Infumorph, 181, 197
- inguinal hernia repair risk of persistent post-operative pain, 45
- injected fentanyl, 448
- chemical formula, 444
- chemical name, 444
- chemical structure, 444
- description, 444
- drug class, 445
- generic name, 444
- manufacturers, 444
- pharmacokinetics, 445
- potential advantages, 448
- potential disadvantages, 448
- proprietary names, 444
- side effects, 448
- inhibitory pain modulation, 11

### Ibu, 215

### ibuprofen injectable
- chemical name, 218
- chemical structure, 218
- common doses, 219
- contraindications, 219
- description, 218
- drug class, 218
- drug related adverse reactions, 221
- generic name, 218
- indications, 218
- manufacturer, 218
- mode of activity, 218
- potential advantages, 220
- potential disadvantages, 221
- precautions, 219
- trade name, 218

### Ildat3m, 115

### hyperalgesia, 30
- allodynia, 24
- clinical implications, 22
- IASP definition, 17
- loss of spinal inhibitory mechanisms, 24
- opioid induced, 77
- primary hyperalgesia, 18
- production of new nerve fibers, 24
- secondary hyperalgesia, 21
- hyperalgesia, 5, 14, 24
- hyperesthesia, 76
- hypoalgesia, 30
- hypoesthesia, 30
- hysterectomy risk of persistent post-operative pain, 46

### Ibu, 215

### Ibdone™, 105

### ibuprofen, 215–217
- chemical name, 215
- chemical structure, 215
- common doses, 216
- contraindications, 216
- description, 215
- drug interactions, 216
- drug related adverse events, 217
- indications (approved/ non-approved), 216
- major sites of action, 215
- metabolic pathways, 215
- mode of activity, 215
- oral suspension, 215

### potential advantages, 216
- potential disadvantages, 217
- receptor interactions, 215
topical creams and gels, 216
toxicity, 216

**See also:** opioid plus ibuprofen compounds.

### ibuprofen oral suspension, 215

### ibuprofen injectable
- chemical name, 218
- chemical structure, 218
- common doses, 219
- contraindications, 219
- description, 218
- drug class, 218
- drug related adverse reactions, 221
- generic name, 218
- indications, 218
- manufacturer, 218
- mode of activity, 218
- potential advantages, 220
- potential disadvantages, 221
- precautions, 219
- trade name, 218

### IL-1 (interleukin-1), 15, 39

### IL-1β, 435

### IL-6, 435

### indomethacin, 229

### inflammatory pain, 15

### inflammatory response, 24–25

### Infumorph, 181, 197

### inguinal hernia repair risk of persistent post-operative pain, 45

### injected fentanyl, 448

### chemical formula, 444

### chemical name, 444

### chemical structure, 444

### description, 444

### drug class, 445

### generic name, 444

### manufacturers, 444

### pharmacokinetics, 445

### potential advantages, 448

### potential disadvantages, 448

### proprietary names, 444

### side effects, 448

### inhibitory pain modulation, 11

### injectable capsacin, 503

### chemical formula, 500

### chemical name, 500

### chemical structure, 500

### clinical trials and doses, 502

### common doses, 503

### contraindications, 502

### description, 501

### drug class, 500

### generic name, 500

### manufacturer, 500

### mode of activity, 501
Index

pharmacokinetics/
pharmacodynamics, 502
potential advantages and
disadvantages, 503
potential indications, 501
trade name, 500
Intensol®, 101
interleukins, 8
International Association for the Study
of Pain (IASP)
definition of hyperalgesia, 17
definition of neuropathic pain, 30
definition of pain, 1, 3
intracranial lesioning, 34
intranasal ketamine. See
ketamine
intranasal
intranasal morphine, 439
intranasal morphine, 439
intrathecal bupropenine, 158
intranasal morphine, 439
intrathecal morphine, 199
analgesic agent, 197
brand names, 197
chemical formula, 197
chemical structure, 197
common doses, 199
contraindications, 198
description, 197
drug related adverse events, 199
indications, 198
mode of activity, 198
potential advantages, 199
potential disadvantages, 199
IONSYS™, 455
iontophoresic transdermal fentanyl, 457
chemical name, 455
chemical structure, 455
contraindications, 456
description, 455
dosing, 456
drug class, 455
generic name, 455
indications, 456
manufacturer, 455
mode of action, 456
potential advantages, 457
potential disadvantages, 457
trade/proprietary name, 455
Isicaine, 279
Ivemend, 401
JNJ-42160443, 512
Jurnista™, 467
Kadian, 86
Keiran™, 316
Keppra, 292
Ketaject™, 316
Ketalar™, 316
Ketalin™, 316
Ketamix™, 316
ketamine, 312, 319
chemical formula, 316
chemical name, 316
chemical structure, 316
chemical structure, 316
common doses, 318
contraindications, 318
description, 316
drug class, 316
drug related adverse events, 319
generic name, 316
indications, 318
manufacturer, 316
mode of activity, 317
potential advantages, 318
potential disadvantages, 319
S (+) ketamine, 312
trade names, 316
ketamine intranasal, 443
brand name, 440
chemical formula, 440
chemical structure, 440
contraindications, 441
description, 440
drug class, 440
efficacy and safety, 443
generic name, 440
indications, 441
manufacturer, 440
mode of activity, 441
Ketam™, 316
ketorolac, 237
chemical structure, 235
common doses, 237
contraindications, 236
description, 236
drug interactions, 237
drug related adverse events, 237
generic name, 235
indications, 236
manufacturer, 235
metabolic activity, 236
mode of activity, 236
potential advantages, 236
potential disadvantages, 237
toxicity, 237
trade name, 235
kinase modulators, 243
Lamictal, 292, 306
Lamicin, 306
Lamogine, 306
lamiotrigin, 292–293
adverse events, 308
brand/proprietary names, 306
chemical name, 306
chemical structure, 306
common doses, 308
contraindications, 307
cost, 308
description, 306
drug class, 306
drug clearance and elimination, 307
generic name, 306
metabolism, 307
mode of activity, 307
potential advantages, 308
Leostesin, 279
Liberaxim™, 115
lidocaine, 267, 270
See also topical local anesthetics, 283
lidocaine for neural blockade, 282
adverse events, 282
chemical names, 279
chemical structure/properties, 280
common doses, 282
contraindications, 282
differential blockade, 282
duration of action, 281
historical development, 280
indications, 282
interaction with hormone replacement therapy, 280
manufacturers, 280
metabolism, 280
mode of activity, 280
onset of action, 281
pharmacodynamics, 280
pharmacokinetcs, 280
potential advantages, 282
potential disadvantages, 282
proprietary names, 279
lidocaine transderal patch, 291
caution, 290
chemical name, 282
chemical structure, 288
contraindications, 290
description, 288
disposal of used patches, 291
dosing, 290
drug related adverse events, 290
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>metaxalone, 361, 374</td>
</tr>
<tr>
<td>chemical formula, 372</td>
</tr>
<tr>
<td>chemical name, 372</td>
</tr>
<tr>
<td>chemical structure, 372</td>
</tr>
<tr>
<td>clinical pearls, 374</td>
</tr>
<tr>
<td>common doses, 373</td>
</tr>
<tr>
<td>contraindications, 373</td>
</tr>
<tr>
<td>cost guide, 373</td>
</tr>
<tr>
<td>drug clearance and elimination, 368</td>
</tr>
<tr>
<td>drug related adverse events, 369</td>
</tr>
<tr>
<td>generic name, 368</td>
</tr>
<tr>
<td>indications (approved/ non-approved), 368</td>
</tr>
<tr>
<td>manufacturer, 368</td>
</tr>
<tr>
<td>metabolism, 368</td>
</tr>
<tr>
<td>mode of activity, 368</td>
</tr>
<tr>
<td>potential disadvantages, 369</td>
</tr>
<tr>
<td>proprietary name, 368</td>
</tr>
<tr>
<td>methyl salicylate, 409</td>
</tr>
<tr>
<td>methylene isoxazolone, 420</td>
</tr>
<tr>
<td>chemical name, 418</td>
</tr>
<tr>
<td>chemical structure, 418</td>
</tr>
<tr>
<td>common dosage, 419</td>
</tr>
<tr>
<td>contraindications, 419</td>
</tr>
<tr>
<td>description, 418</td>
</tr>
<tr>
<td>drug class, 418</td>
</tr>
<tr>
<td>drug related adverse events, 420</td>
</tr>
<tr>
<td>generic name, 418</td>
</tr>
<tr>
<td>indications (approved/ non-approved), 418</td>
</tr>
<tr>
<td>major and minor sites of action, 418</td>
</tr>
<tr>
<td>methylphenidate, 399–400</td>
</tr>
<tr>
<td>chemical name, 368</td>
</tr>
<tr>
<td>chemical structure, 368</td>
</tr>
<tr>
<td>common doses, 369</td>
</tr>
<tr>
<td>contraindications, 368</td>
</tr>
<tr>
<td>description, 368</td>
</tr>
<tr>
<td>drug class, 368</td>
</tr>
<tr>
<td>drug clearance and elimination, 368</td>
</tr>
<tr>
<td>drug related adverse events, 369</td>
</tr>
<tr>
<td>generic name, 368</td>
</tr>
<tr>
<td>indications (approved/ non-approved), 368</td>
</tr>
<tr>
<td>manufacturer, 368</td>
</tr>
<tr>
<td>metabolism, 368</td>
</tr>
<tr>
<td>mode of activity, 368</td>
</tr>
<tr>
<td>potential disadvantages, 369</td>
</tr>
<tr>
<td>proprietary name, 368</td>
</tr>
<tr>
<td>morphine</td>
</tr>
<tr>
<td>history of, 73</td>
</tr>
<tr>
<td>morphine (oral and parenteral), 82–85</td>
</tr>
<tr>
<td>chemical name, 82</td>
</tr>
<tr>
<td>chemical structure, 82</td>
</tr>
<tr>
<td>class, 82</td>
</tr>
<tr>
<td>common doses, 83</td>
</tr>
<tr>
<td>common side effects, 85</td>
</tr>
<tr>
<td>contraindications, 83</td>
</tr>
<tr>
<td>drug clearance and elimination, 83</td>
</tr>
<tr>
<td>drug interaction, 85</td>
</tr>
<tr>
<td>treatment of adverse effects, 85</td>
</tr>
<tr>
<td>fertility, 84</td>
</tr>
<tr>
<td>generic names, 82</td>
</tr>
<tr>
<td>indications, 83</td>
</tr>
<tr>
<td>lactation, 84</td>
</tr>
<tr>
<td>major and minor sites of action, 82</td>
</tr>
<tr>
<td>manufacturers, 82</td>
</tr>
<tr>
<td>morphine pathway, 83</td>
</tr>
<tr>
<td>multimodal analgesia, 85</td>
</tr>
<tr>
<td>potential advantages, 84</td>
</tr>
<tr>
<td>potential disadvantages, 84</td>
</tr>
<tr>
<td>pregnancy, 84</td>
</tr>
<tr>
<td>receptor interactions, 84</td>
</tr>
<tr>
<td>trade/proprietary names, 84</td>
</tr>
<tr>
<td>treatment of adverse effects, 85</td>
</tr>
<tr>
<td>morphine intranasal. See intranasal morphine</td>
</tr>
<tr>
<td>morphine neuraxial</td>
</tr>
<tr>
<td>See epidural morphine; extended-release epidural morphine; intrathecal morphine</td>
</tr>
<tr>
<td>morphine sulfate controlled-release, 86</td>
</tr>
<tr>
<td>absorption, 86</td>
</tr>
<tr>
<td>chemical structure, 86</td>
</tr>
<tr>
<td>common doses, 88</td>
</tr>
<tr>
<td>contraindications, 88</td>
</tr>
<tr>
<td>drug class, 86</td>
</tr>
<tr>
<td>drug related adverse events, 89</td>
</tr>
<tr>
<td>excrination, 87</td>
</tr>
<tr>
<td>formulations, 86</td>
</tr>
<tr>
<td>generic names, 86</td>
</tr>
<tr>
<td>indications (approved/ non-approved), 86</td>
</tr>
<tr>
<td>manufacturers, 86</td>
</tr>
<tr>
<td>metabolic pathway, 87</td>
</tr>
<tr>
<td>metabolism, 87</td>
</tr>
<tr>
<td>mode of activity, 86</td>
</tr>
<tr>
<td>potential advantages, 86</td>
</tr>
<tr>
<td>potential disadvantages, 86</td>
</tr>
<tr>
<td>sites of activity, 86</td>
</tr>
<tr>
<td>trade/proprietary names, 86</td>
</tr>
<tr>
<td>treatment of adverse events, 89</td>
</tr>
</tbody>
</table>

© in this web service Cambridge University Press www.cambridge.org
<table>
<thead>
<tr>
<th>Brand NAME</th>
<th>Chemical formula</th>
<th>Chemical name</th>
<th>Chemical structure</th>
<th>Nerve pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>morphine-6-glucuronide</td>
<td>478</td>
<td>chemical structure, 475</td>
<td>description, 475</td>
<td>disadvantages, 477</td>
</tr>
<tr>
<td>drug class, 475</td>
<td>generic name, 475</td>
<td>manufacturer/developers, 475</td>
<td>metabolism, 475</td>
<td>pharmacodynamics, 476</td>
</tr>
<tr>
<td>pharmacokinetics, 476</td>
<td>potential advantages and uses, 477</td>
<td>randomized controlled trials, 478</td>
<td>motor cortex stimulation, 35</td>
<td>Motor cortex stimulation, 35</td>
</tr>
<tr>
<td>MotrinTM, 215</td>
<td>MRI</td>
<td>use of lidocaine transdermal patch, 290</td>
<td>MS Contin®, 86</td>
<td>Multidisciplinary approach</td>
</tr>
<tr>
<td>neuropathic pain management, 34</td>
<td>multidisciplinary pain centers, 34</td>
<td>multimodal analgesia, 275</td>
<td>acetaminophen (paracetamol), 59</td>
<td>alpha-2 adrenergic agonists, 62</td>
</tr>
<tr>
<td>anticonvulsants, 60</td>
<td>antidepressants, 62</td>
<td>COX-2 inhibitors, 59</td>
<td>local anesthetics, 59</td>
<td>anticonvulsants, 60</td>
</tr>
<tr>
<td>morphine, 85</td>
<td>NMDA receptor antagonists, 61</td>
<td>NSAIDs, 58</td>
<td>opioids, 58</td>
<td>SNRIs, 62</td>
</tr>
<tr>
<td>NMDA receptor antagonists, 61</td>
<td>NMDA receptor antagonists, 61</td>
<td>NSAIDs, 58</td>
<td>opioids, 58</td>
<td>SNRIs, 62</td>
</tr>
<tr>
<td>TCAs (tricyclic antidepressants), 61</td>
<td>multi-segmental flexion reflexes, 5</td>
<td>muscle relaxants in pain management</td>
<td>baclofen, 363, 364</td>
<td>carisoprodol, 361</td>
</tr>
<tr>
<td>chlorzoxazone, 360</td>
<td>cyclobenzaprine, 362</td>
<td>diazepam (Valium), 362</td>
<td>guaifenesin, 360</td>
<td>meprobamate, 361</td>
</tr>
<tr>
<td>metaxalone, 361</td>
<td>methocarbamol, 360</td>
<td>orphenadrine, 361</td>
<td>prescribing considerations, 364</td>
<td>tizanidine, 363</td>
</tr>
<tr>
<td>baclofen, 363</td>
<td>carisoprodol, 361</td>
<td>chlorzoxazone, 360</td>
<td>cyclobenzaprine, 362</td>
<td>metaxalone, 361</td>
</tr>
<tr>
<td>methocarbamol, 360</td>
<td>orphenadrine, 361</td>
<td>prescribing considerations, 364</td>
<td>tizanidine, 363</td>
<td>muscle spasm, 5</td>
</tr>
<tr>
<td>myalgic pain, 6</td>
<td>myofascial pain, 16</td>
<td>Nabilone. See cannabinoid agonists N-acetyl-para-aminophenol (APAP).</td>
<td>See acetaminophen</td>
<td>Nalbuphine</td>
</tr>
<tr>
<td>Nalbuphine</td>
<td>abuse liability, 153</td>
<td>adverse reactions, 153</td>
<td>brand names, 150</td>
<td>chemical formula, 150</td>
</tr>
<tr>
<td>chemical name, 150</td>
<td>chemical structure, 150</td>
<td>contraindications, 153</td>
<td>description, 151</td>
<td>dosage, 152</td>
</tr>
<tr>
<td>drug class, 150</td>
<td>drug interactions, 152</td>
<td>formulation, 153</td>
<td>generic name, 150</td>
<td>indications, 151</td>
</tr>
<tr>
<td>manufacturers, 150</td>
<td>pharmacokinetics, 151</td>
<td>routes of administration, 153</td>
<td>Naropen®17, 221</td>
<td>naproxen, 225</td>
</tr>
<tr>
<td>potential advantages/ disadvantages, 508</td>
<td>preliminary analgesic trials, 507</td>
<td>nerve growth factor (NGF), 14</td>
<td>nerve pain. See neuropathic pain</td>
<td>neuraxial clonidine hydrochloride</td>
</tr>
<tr>
<td>black box warning, 333</td>
<td>chemical name, 332</td>
<td>chemical structure, 332</td>
<td>common doses, 333</td>
<td>contraindications, 333</td>
</tr>
<tr>
<td>medication, 332</td>
<td>metabolic pathways, 333</td>
<td>mode of activity, 333</td>
<td>potential advantages, 334</td>
<td>potential disadvantages, 334</td>
</tr>
<tr>
<td>receptor interactions, 333</td>
<td>trade/proprietary names, 332</td>
<td>neuropathic pain, 3–4, 15–16</td>
<td>assessment, 30</td>
<td>causes, 30</td>
</tr>
<tr>
<td>diagnosis, 30</td>
<td>IASP definition, 30</td>
<td>perception abnormalities, 30</td>
<td>pharmacological management, 17</td>
<td>scales and questionnaires, 30</td>
</tr>
<tr>
<td>screening tools, 30</td>
<td>sensory abnormalities, 30</td>
<td>sensory examination, 30</td>
<td>types of, 30</td>
<td></td>
</tr>
</tbody>
</table>
### Index

<table>
<thead>
<tr>
<th>Neuropathic Pain Management</th>
<th>Behavioral Treatments, 33</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive Therapy, 33</td>
<td>Interdisciplinary Team Approach, 34</td>
</tr>
<tr>
<td>Intervventional Management, 35</td>
<td></td>
</tr>
<tr>
<td>Multidisciplinary Treatment, 34</td>
<td></td>
</tr>
<tr>
<td>Nerve Blocks, 34</td>
<td></td>
</tr>
<tr>
<td>Neuroablative Procedures, 34</td>
<td></td>
</tr>
<tr>
<td>Neurostimulation, 35</td>
<td></td>
</tr>
<tr>
<td>Non-Pharmacological Approaches, 34</td>
<td></td>
</tr>
<tr>
<td>Pharmacological Management, 31</td>
<td></td>
</tr>
<tr>
<td>Psychological Interventions, 32</td>
<td></td>
</tr>
<tr>
<td>Rehabilitation, 32</td>
<td></td>
</tr>
</tbody>
</table>

| Nicotinic Receptor Agonists/ Antagonists, 436 |
| Adverse Effects, 487 |
| Generic Name, 484 |
| Indications (non-FDA-approved), 486 |
| Manufacturers, 484 |
| Mechanism of Action, 485 |
| Metabolism, 485 |
| Pharmacokinetics, 485 |
| Potential Advantages, 487 |
| Potential Disadvantages, 487 |
| Pregnancy, 486 |
| Trade/Proprietary Names, 484 |

| Nociception, 3, 11 |
| Activation of Sensory End Organs and/or Nerve Endings, 8 |
| and Subjective Experience of Pain, 14 |
| Ascending Tracts, 11 |
| Conduction of Pain to the Spinal Cord and Medulla, 11 |
| Descending Neural Pathways, 12 |
| Objective Measurement, 14 |
| Stages in Pain Transmission, 7 |
| Transmission of Impulses from Spinal Cord to Supra-Spinal Structures, 11 |
| Nociceptive Nerve Fibers, 8 |
| Nociceptive Pain, 3–4, 15 |
| Nociceptors, 3 |
| Pain Detection and Signaling, 1 |
| Nonsteroidal Anti-Inflammatory Drugs, 211 |

| NSAIDs, 212–213 |
| Adverse Effects, 211 |
| Mechanism of Action, 212 |
| Postoperative Pain Management, 212 |
| Role in Multimodal Analgesia, 211 |
| Role in Preemptive Analgesia, 212 |

| Nubain™, 150 |
| Nuclear Receptors, 24 |
| Nucleus Raphe Magnus, 57 |

| Nucynta™, 143 |
| Numorphan Injectable™, 119 |
| Nuprin, 215 |
| Nurofen Plus®, 98 |
| Opioid Agonist Plus Antagonist Analgesics, 115 |

| Opioid Agonist Plus Antagonist Analgesics, 115 |
| Abuse Liability, 93 |
| Abuse of Prescription Opioids, 91 |
| Chemical Structures, 90 |
| Drug Class, 90 |
| Future Combinations, 93 |
| Generic Names, 90 |
| Manufacturers, 90 |
| Morphine Plus Naltrexone Combination, 92–93 |
# Index

| opioid agonist and antagonist combinations, 92 | disadvantages, 107 |
| trade/proprietary names, 90 | proprietary names, 105 |
| opioid analogesics, 80 | side effects, 107 |
| benefits and liabilities, 73 | opioid receptors, 74 |
| drug related adverse events, 80 | delta receptors (OPR1), 73–74 |
| future directions for acute pain treatment, 80 | kappa receptors (OPR2), 73–74 |
| history of, 73 | mu receptors (OPR3), 73–74 |
| hyperalgesia, 77 | sigma-1 receptors, 74 |
| opioid tolerance and dependence, 77 | sigma receptors, 73 |
| oral analgesic dosing, 79 | opioid rotation, 179 |
| parenteral opioid therapy, 78 | adverse effects of opioid analogesics, 175 |
| pharmacokinetics, 76 | guidelines, 179 |
| regulation of, 73 | patient variabilities in opioid response, 176 |
| opioid classification, 77 | tolerability of opioid analogesics, 175 |
| opioid dependence, 76 | opioid tolerance, 77, 167 |
| meanings of the term, 170 | acquired tolerance, 167 |
| pain management in dependent patients, 170 | addiction, 76 |
| types of patients, 165 | development of, 166 |
| withdrawal syndrome, 169 | innate tolerance, 166 |
| opioid dosing in pediatric patients, 165–169 | learned tolerance, 166 |
| age classification for pediatric patients, 161 | pain management in opioid tolerant patients, 170 |
| general principles of pain management, 161–162 | pharmacodynamic tolerance, 167 |
| initial opiate dosage guide (patients over 6 months old), 162–164 | physical dependence, 76 |
| initial opiate dosage guide (patients under 6 months old), 164–165 | pseudo-addiction, 165 |
| opioids as anesthetics (patient under 6 months old), 164–165 | psychological dependence, 76 |
| routine postoperative analgesia, 165 | types of, 167 |
| opioid hyperalgesia, 171 | types of patients, 165 |
| opioid induced hyperalgesia characteristics, 171 | opioid-induced abnormal pain, 171 |
| clinical and management implications, 174 | sensitivity, 171 |
| pathophysiology, 172 | opioid-induced paradoxical pain, 171 |
| recognition of the condition, 171 | opioids, 171 |
| opioid plus ibuprofen compounds chemical names, 105 | sites of analgesic activity, 59–60 |
| chemical structure of individual drugs, 105 | tamper resistant. See tamper resistant opioids |
| common doses (oral), 107 | ORADUR™ technology, 465 |
| contraindications, 107 | oral opioid analogesics, 79 |
| description, 105 | oral salicylate See aspirin |
| drug class, 105 | Orasone®, 388 |
| drug clearance and elimination, 106 | OROS™ technology, 465 |
| generic names, 105 | Orphanin/FQ, 508 |
| indications (approved/non-approved), 106 | orphenadrine, 361 |
| major and minor sites of action, 105 | OXN™, 90 |
| manufacturers, 105 | Oxy IR®, 101 |
| metabolic pathways, 106 | oxycodone, 101–104 |
| opioid-sparing effects, 107 | chemical formula, 101 |
| potential advantages and metabolic tolerance and elimination, 101 |
| disadvantages, 107 | mode of activity, 101 |
| proprietary names, 105 | patients with hepatic impairment, 102 |
| side effects, 107 | patients with renal impairment, 102 |
| opioid receptors, 74 | potential advantages, 103 |
| delta receptors (OPR1), 73–74 | potential disadvantages, 103 |
| kappa receptors (OPR2), 73–74 | proprietary names, 101 |
| mu receptors (OPR3), 73–74 | respiratory depression, 102 |
| sigma-1 receptors, 74 | See also opioid plus ibuprofen compounds, 105 |
| sigma receptors, 73 | oxycodone compounds generic names, 101 |
| opioid rotation, 179 | manufacturers, 101 |
| adverse effects of opioid analogesics, 175 | proprietary names, 101 |
| guidelines, 179 | oxycodone controlled release chemical formula, 108 |
| patient variabilities in opioid response, 176 | chemical name, 108 |
| tolerability of opioid analogesics, 175 | chemical structure, 108 |
| opioid tolerance, 77, 167 | contraindications, 110 |
| acquired tolerance, 167 | cost/street price, 111 |
| addiction, 76 | description, 108 |
| development of, 166 | dosage, 110 |
| innate tolerance, 166 | drug abuse and addiction, 111 |
| learned tolerance, 166 | drug class, 108 |
| management in opioid tolerant patients, 170 | drug clearance and elimination, 109 |
| pharmacodynamic tolerance, 167 | drug interactions, 111 |
| pharmacokinetic tolerance, 166 | drug related adverse events, 111 |
| physical dependence, 76 | formulations, 111 |
| pseudo-addiction, 165 | generic name, 108 |
| psychological dependence, 76 | how supplied, 111 |
| types of, 167 | indications, 109 |
| types of patients, 165 | manufacturer, 108 |
| opioid-induced abnormal pain, 171 | metabolic pathways, 109 |
| sensitivity, 171 | mode of activity, 109 |
| opioid-induced paradoxical pain, 171 | potential advantages, 110 |
| opioids, 171 | potential disadvantages, 111 |
| sites of analgesic activity, 59–60 | proprietary name, 108 |
| tamper resistant. See tamper resistant opioids | toxicity, 111 |
| ORADUR™ technology, 465 | Oxycontin®, 108 |
| oral opioid analogesics, 79 | Oxydose®, 101 |
| oral salicylate See aspirin | Oxyfast®, 101 |
| Orobin®, 388 | oxycodeine extended release, 123–127 |
| OROS™ technology, 465 | absorption, 124 |
| Orphanin/FQ, 508 | chemical formula, 102 |
| orphenadrine, 361 | chemical name, 102 |
| OXN™, 90 | chemical structure, 123 |
| Oxy IR®, 101 | common doses, 126 |
| oxycodone, 101–104 | contraindications, 125 |
| chemical formula, 101 | description, 124 |
| chemical name, 101 | drug class, 123 |
| chemical structure, 101 | drug clearance and elimination, 124 |
| common doses/uses, 103 | drug related adverse events, 127 |
| contraindications, 102 | generic name, 123 |
| description, 101 | indications, 125 |
| drug class, 101 | manufacturers, 123 |
| drug related adverse effects, 104 | metabolic pathways, 124 |
| generic name, 101 | metabolism, 125 |
| indications, 102 | mode of activity, 124 |
potential advantages, 126
potential disadvantages, 126
proprietary name, 123
routes of administration, 126
oxymorphone injectable, 122
acute pain management, 121
chemical formula, 119
chemical name, 119
clinical pharmacology, 121
common doses, 121
contraindications, 121
conversion from oral OPANA to OPANA injection, 122
cost, 122
description, 119
drug class, 119
drug interactions, 122
drug related adverse events, 122
genetic name, 119
historical overview, 120
indications, 121
IV-PCA (patient-controlled analgesic), 121
labor analgesia, 122
manufacturers, 119
preparations, 122
proprietary names, 119
uses, 121
OxytrexTM, 90
Ozurdex®, 388

pain
effects on recovery, 3
incidence among patients, 3
reasons for minimising discomfort, 3
pain classifications, 4
temporal classifications, 14
pain definitions
IASP definition, 1, 3
pain detection
nociceptors, 1
pain experience
and nociception, 14
pain ladder method of controlling pain, 211
pain management
guidelines for a four step approach, 69
moving towards a flexible approach, 71
rationale for a four step approach, 67
traditional three step approach, 66
pain pathophysiology
cardiac effects, 27
CNS pathophysiology, 24
definition of pathologic pain, 23
emotional and quality of life effects, 28
humoral and hormonal responses, 27
peripheral nervous system, 25
pulmonary effects, 27
vascular effects, 27
venous thrombotic effects, 28
pain perception
qualitative aspects, 6
pain signaling, 1
pain temporality and duration, 6
PainEase. See vapocoolant spray (PainEase)
paleo-spinohalamic tract (pSTT), 11
PallidoneTM, 448
Pamelor TM, 347

paracetamol. See acetaminophen
parecoxib, 213
chemical formula, 245
chemical structure, 245
generic name, 245
manufacturer, 245
trade/proprietary name, 245

peripheral kappa agonist, 491
chemical name, 490
chemical structure, 490
description, 490
drug abuse and dependence, 491
drug class, 490
drug related adverse events, 491
genetic name, 490
indications (non-approved), 490
manufacturer/developer, 490
mechanism of action, 490
pharmacokinetics, 490
potential advantages, 491
potential disadvantages, 491
trade/proprietary name, 490
toxicity, 499

peripheral cannabinoid receptor agonists
adverse events, 500
availability, 500
chemical structures, 497
contraindications, 499
description, 499
drug class, 497
drug interactions, 499
genetic names, 497
indications (approved/non-approved), 499
manufacturer, 497
metabolic pathways, 499
mode of activity, 499
potential advantages, 499
potential disadvantages, 500
proprietary names, 497

peripheral nervous system pain pathophysiology, 25
peripheral sensitization, 25
persistent post-operative pain abdominal hysterectomy, 46
amputation, 46
breast surgery, 46
central nervous system involvement, 43
Cesarean section, 46
consequences, 41
definition, 41
epidemiology, 41
genetic risk factors, 48
historical background, 41
identifying patients at risk, 48
inguinal hernia repair, 45
mechanisms, 45
neuronal plasticity, 45
non-nerve structures involved, 43
pain processes, 43
patient risk factors, 47
predicting, 48

Index
Index

risk factors, 48
risk with various operative procedures, 46
significance, 42
spinal cord involvement, 43
structures involved, 43
surgical/medical risk factors, 48
thoracic surgery, 45
persistent post-operative pain management, 49–51
future directions for treatment, 50
multimodal treatment, 50
pre-emptive/preventive treatment, 49
prevention, 49
phantom limb pain, 46
pharmacological management of neuropathic pain, 17, 31
Phenergan®, 391
phenylbutazone, 229
phenytoin, 292
physiological pain, 3–4
plasticity neuronal regeneration, 16
PMS HydromorphoneTM, 115
PolistirexTM, 321
poorly controlled pain cardiac effects, 27
catecholamine responses, 26
electromotor responses, 28
neuroendocrine responses, 27
pulmonary effects, 27
quality of life effects, 28
stress response to injury, 27
vascular effects, 27
venous thrombotic effects, 28
postherpetic neuralgia, 23
post-operative pain
See also persistent post-operative pain.
potassium (K+) channels, 435
Predicex®, 335
prednisone
chemical name, 388
chemical structure, 388
common doses and uses, 390
contraindications, 390
drug class, 388
drug interactions, 390
drug related adverse events, 390
generic name, 388
indications, 389
manufacturers, 388
mode of activity, 389
potential advantages, 390
potential disadvantages, 390
proprietary names, 388
side effects, 390
Prednisone®, 388
preemptive analgesia, 212
pregabalin, 292–293
chemical formula, 298
chemical name, 298
cellular structure, 298
contraindications, 299
description, 298
drug related adverse effects, 300
generic name, 298
indications, 300
manufacturer, 298
mechanism of action, 298
overdose, 300
pharmacokinetics, 299
potential advantages, 300
potential disadvantages, 300
routes of administration, 299
trade name, 298
Prialt™, 415
prilocaine, 270, See EMLATM primary hyperalgesia, 18, 23
proacaine, 267
prostaglandins (PGs), 8
ProStep, 484
protein kinase A (PKA), 25
protein kinase C (PKC), 25
pseudo-addiction, 165
pulmonary effects of poorly controlled pain, 27
purinergic (P2X) receptors, 8
purinoreceptors, 433–434
qualitative aspects of pain perception, 6
quality of life effects of poorly controlled pain, 28
referred pain, 3
regeneration of damaged neurons, 16
rehabilitative/convalescent pain, 5
Relistor™, 418
remifentanil, 150
cellular formula, 147
cellular name, 147
chemical structure, 147
common doses, 149
contraindications, 149
description, 148
drug class, 147
drug related adverse events, 150
generic name, 147
manufacturers, 147
mode of activity, 148
potential advantages, 149
potential disadvantages, 149
trade name, 147
RemoxyTM, 465
RexipainTM, 105
ResTiva™, 481
Rexista, 465
Reye's syndrome, 253, 255
Robafen AC®, 98
Robaxin®, 368
Robaxin, 360
Robitussin A-C” Syrup, 98
Robitussin™ DM, 321
rofecoxib, 213
ropivacaine, 279
absorption, 277
brand names, 276
cellular name, 276
cellular structure, 276
clinical recommendations, 279
cellular indications, 279
description, 276
distribution, 277
dosing and timing, 279
elimination, 277
generic name, 276
indications, 278
mechanism of action, 277
metabolism, 277
pharmacokinetics, 277
strength descriptions, 276
toxicity, 279
warnings, 279
Roxicet™, 101
Roxicodone®, 101
R oxiprin®, 101
Rucaina, 279
RylomineTM, 437
S (+) ketamine, 312
Sativex. See cannabinoid agonists SavellaTM, 357
scopolamine. See transdermal scopolamine
secondary hyperalgesia, 5, 21, 23
selective serotonin reuptake inhibitors (SSRIs), 338
Sensorcaine, 274
serotonin, 8
serotonin and norepinephrine reuptake inhibitors (SNRIs), 341
sites of analgesic activity, 62
serotonin syndrome, 341
silent nociceptors, 15
SinequanTM, 347
Sirdalud™, 375
sites of analgesic activity, 62
Skelaxin™, 357
sodium (Na+) channels, 434
SolarazeTM, 229
Soma, 360
somatic pain, 3, 14
SophidoneTM, 115
spinal cord stimulation, 35
Index

spinothalamic tract (STT), 11
splintering, 5
Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP), 344
stress response to injury, 27
subcutaneous extended release sufentanil, 467, 470
Sublimaze™, 184
sublingual buprenorphine, 159
substance P, 8, 14–15
Sufenta, 191
sufentanil. See epidural sufentanil
surgical factors
risk of persistent post-operative pain, 48
Symmetrel®, 325
Synera™, 286
contraindications, 286
description, 286
generic name, 283
how to use, 286
manufacturer, 283
mode of action, 286
pharmacology, 286
potential advantages, 286
potential disadvantages, 286
trade/proprietary name, 283
Tagamet®, 391
tamper resistant opioids,
Acurox™ formulation, 466
approaches to tamper resistance, 466
DETERx technology, 465
drug class, 463
EDACS, 465
EMBEDA™, 466
generic names, 463
manufacturers, 463
OROSTM technology, 465
prescription opioid abuse, 463
Remoxy™, 465
trade/proprietary names, 463
Tanezumab™, 513
tapentadol, 143–147
combined formula, 143
combined name, 143
combined structure, 143
common doses, 146
contraindications, 146
description, 144
drug class, 143
drug related adverse events, 151
generic name, 143
indications, 146
manufacturer, 143
mode of activity, 146
potential advantages, 146
potential disadvantages, 147
relative contraindications, 146
trade name, 143
tapentadol ER, 458–462
combined formula, 458
combined name, 458
combined structure, 458
clinical investigations, 461
common doses, 461
contraindications, 461
description, 458
drug class, 458
drug related adverse events, 461
generic name, 458
indications, 459
manufacturer, 458
mode of activity, 459
potential advantages, 461
potential disadvantages, 461
trade name, 458
warnings, 461
Taufix, 247
Tegetrol, 292, 301
Temesta, 365
temporal classifications of pain, 14
drug-drug interactions, 376
terminal pain, 14
temporal summation, 24
Ternelin™, 375
tetracaine. See Ametop Gel™; Synera™
thermal hyperalgesia, 14
thoracic surgery
risk of persistent post-operative pain, 45
three step approach to pain management, 66
tissue pain (nociceptive pain), 15
tizanidine, 363, 378
absorption, 376
central formula, 375
central name, 375
central structure, 375
clinical effects, 376
comparative standing, 378
contraindications, 378
cost, 378
description, 375
dosing guidelines, 378
drug class, 375
drug clearance and elimination, 376
drug interactions, 378
generic name, 375
how supplied, 378
indications, 377
manufacturer, 375
metabolism, 376
mode of action, 376
pharmacokinetics, 376
side effects, 377
tablet vs. capsule, 376
toxicity, 378
trade/proprietary names, 375
tizanidinu™, 375
Tofranil™, 347
Topamax, 292
topical capsaicin, 408
combined structure, 407
contraindications, 409
description, 407
how to use in pain management, 409
mode of activity, 408
pharmacology, 408
potential advantages, 409
potential disadvantages, 409
side effects, 409
topical local anesthetics, 285–287
Ametop Gel™ (amethocaine gel), 287
EMLA™ (Eutectic Mixture of Local Anesthetics), 285
generic names, 283
LMX-4™ (liposomal lidocaine), 285
manufacturers, 283
Synera™ (lidocaine/tetracaine topical patch), 286
trade/proprietary names, 283
vapocoolant spray (PainEase), 287
topical salicylates, 412
combined structure, 410
common doses/uses, 412
contraindications, 411
diethylamine salicylate, 410
drug related adverse events, 412
indications (approved/non-approved), 411
methyl salicylate, 410
mode of activity, 411
potential advantages, 412
potential disadvantages, 412
trolamine salicylate, 410
Toradol™, 235
tramadol, 137
advantages, 139
adverse events, 139
combined formula, 137
combined name, 137
combined structure, 137
contraindications, 139
description, 137
disadvantages, 139
drug class, 137
generic name, 137
indications, 137
manufacturers, 137
metabolism, 138
mode of action, 137
preparations, 139–140
structural formula, 137
trade/proprietary names, 137
Index

tramadol extended release, 140–143
chemical formula, 140
chemical name, 140
chemical structure, 140
common doses, 141
contraindications, 141
description, 141
drug class, 140
drug related adverse events, 143
generic name, 140
indications, 141
manufacturers, 140
mode of activity, 141
potential advantages, 142
potential disadvantages, 143
trade/proprietary name, 140

tramadol plus acetaminophen
adverse events, 139
description, 137
drug class, 137
generic name, 137
indications, 139
manufacturers, 137
structural formula, 137
trade/proprietary names, 137

Tramal, 137

transcutaneous electrical stimulation (TENS), 35
Transderm Scop™, 405
transdermal extended release
sufentanil, 467, 471
transdermal scopolamine, absorption, 405
adverse events, 407
chemical formula, 405
chemical name, 405
chemical structure, 405
common doses, 406
contraindications, 406
description, 405
drug class, 405
drug interactions, 407
drug related adverse events, 407
generic name, 405
indications, 406
major site of action, 405
manufacturer, 405
metabolism, 405
mode of activity, 405
potential advantages, 406
potential disadvantages, 407
proprietary name, 405
TRANSIDUR™, 467
transient receptor potential (TRP) channels, 8
Transtecc™, 481
trazodone, 351–353
chemical formula, 351
chemical name, 351

chemical structure, 351
common doses, 352
contraindications, 352
description, 351
disease related concerns, 353
drug class, 351
drug clearance and elimination, 351
drug related adverse events, 352
generic name, 351
indications, 352
major drug interactions, 352
manufacturers, 351
metabolic pathways, 351
mode of activity, 351
overdose, 353
potential advantages, 352
potential disadvantages, 353
proprietary name, 351

tricyclic antidepressants (TCAs), 338, 350

valdecoxib, 213, 245
Valium, 362, 365
vanilloid receptors (VRI), 8
vapocoolant spray (PainEase), 287
chemical structure, 287
contraindications, 287
description, 287
generic name, 283
how to use, 287
manufacturer, 283
mode of action, 287
pharmacology, 287
potential advantages, 287
potential disadvantages, 287
trade/proprietary name, 283
vascular effects of poorly controlled
pain, 27
venous thrombotic effects of poorly
controlled pain, 28
Vicodin CR™, 452
Vicodin™ Controlled Release, 452
Vicoprofen™, 105
Vioxx, 213
visceral pain, 3, 14
Vistaril™, 391
Vivacaine, 274
Vivactil™, 347
Voltaren® Gel, 225
VoltarenTM, 229
Voltaren-XRTM, 229
wind-up phenomenon, 9, 212
withdrawal syndrome, 169
World Health Organization (WHO)
algesic ladder, 66, 253
pain ladder method of controlling
pain, 211
Xylostanol, 279
### Index

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylocaine</td>
<td>279</td>
</tr>
<tr>
<td>Xylocitin</td>
<td>279</td>
</tr>
<tr>
<td>Xylotox</td>
<td>279</td>
</tr>
<tr>
<td>Xyzal®</td>
<td>391</td>
</tr>
<tr>
<td>Zanaflex</td>
<td>363</td>
</tr>
<tr>
<td>Zanaflex™</td>
<td>375</td>
</tr>
<tr>
<td>Zantac®</td>
<td>391</td>
</tr>
<tr>
<td>Zarontin</td>
<td>292</td>
</tr>
<tr>
<td>Ziconotide</td>
<td>415–417</td>
</tr>
<tr>
<td>adverse events</td>
<td>417</td>
</tr>
<tr>
<td>chemical formula</td>
<td>415</td>
</tr>
<tr>
<td>chemical structure</td>
<td>415</td>
</tr>
<tr>
<td>common doses</td>
<td>416</td>
</tr>
<tr>
<td>contraindications</td>
<td>415</td>
</tr>
<tr>
<td>description</td>
<td>415</td>
</tr>
<tr>
<td>drug class</td>
<td>415</td>
</tr>
<tr>
<td>drug interactions</td>
<td>417</td>
</tr>
<tr>
<td>elimination</td>
<td>415</td>
</tr>
<tr>
<td>generic name</td>
<td>415</td>
</tr>
<tr>
<td>indications (approved/non-approved)</td>
<td>415</td>
</tr>
<tr>
<td>manufacturer</td>
<td>415</td>
</tr>
<tr>
<td>metabolism</td>
<td>415</td>
</tr>
<tr>
<td>mode of activity</td>
<td>415</td>
</tr>
<tr>
<td>potential advantages</td>
<td>416</td>
</tr>
<tr>
<td>potential disadvantages</td>
<td>417</td>
</tr>
<tr>
<td>toxicity</td>
<td>416</td>
</tr>
<tr>
<td>trade/proprietary name</td>
<td>415</td>
</tr>
<tr>
<td>Zonegran</td>
<td>292</td>
</tr>
<tr>
<td>Zydol</td>
<td>137</td>
</tr>
<tr>
<td>Zyrtec®</td>
<td>391</td>
</tr>
</tbody>
</table>